N4 Pharma PLC Total Voting Rights (2196O)
29 Mayo 2020 - 11:00AM
UK Regulatory
TIDMN4P
RNS Number : 2196O
N4 Pharma PLC
29 May 2020
29 May 2020
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
Total Voting Rights
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, announces the Company's issued ordinary share capital
as at the date of this announcement comprises 152,193,787 ordinary
shares, with one voting right each. The Company does not hold any
ordinary shares in treasury. Therefore, the total number of
ordinary shares and voting rights in the Company is
152,193,787.
The above figure may be used by shareholders in the Company as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Scott PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Turner Pope Investments Tel: +44(0)20 3657 0050
(TPI) Ltd
Andrew Thacker
Scott PR
Georgia Smith Tel: +44(0)1477 539 539
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRKKFBQFBKKCPB
(END) Dow Jones Newswires
May 29, 2020 12:00 ET (16:00 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024